Multi-Omics Disease Characterization Pipeline

Characterize diseases across multiple molecular layers (genomics, transcriptomics, proteomics, pathways) to provide systems-level understanding of disease mechanisms, identify therapeutic opportunities, and discover biomarker candidates.

KEY PRINCIPLES:

1. Report-first approach - Create report file FIRST, then populate progressively
2. Disease disambiguation FIRST - Resolve all identifiers before omics analysis
3. Layer-by-layer analysis - Systematically cover all omics layers
4. Cross-layer integration - Identify genes/targets appearing in multiple layers
5. Evidence grading - Grade all evidence as T1 (human/clinical) to T4 (computational)
6. Tissue context - Emphasize disease-relevant tissues/organs
7. Quantitative scoring - Multi-Omics Confidence Score (0-100)
8. Druggable focus - Prioritize targets with therapeutic potential
9. Biomarker identification - Highlight diagnostic/prognostic markers
10. Mechanistic synthesis - Generate testable hypotheses
11. Source references - Every statement must cite tool/database
12. Completeness checklist - Mandatory section showing analysis coverage
13. English-first queries - Always use English terms in tool calls. Respond in user's language

When to Use This Skill

Apply when users:

• Ask about disease mechanisms across omics layers
• Need multi-omics characterization of a disease
• Want to understand disease at the systems biology level
• Ask "What pathways/genes/proteins are involved in [disease]?"
• Need biomarker discovery for a disease
• Want to identify druggable targets from disease profiling
• Ask for integrated genomics + transcriptomics + proteomics analysis
• Need cross-layer concordance analysis
• Ask about disease network biology / hub genes

NOT for (use other skills instead):

• Single gene/target validation -> Use

  tooluniverse-drug-target-validation

• Drug safety profiling -> Use

  tooluniverse-adverse-event-detection

• General disease overview -> Use

  tooluniverse-disease-research

• Variant interpretation -> Use

  tooluniverse-variant-interpretation

• GWAS-specific analysis -> Use

  tooluniverse-gwas-*

  skills
• Pathway-only analysis -> Use

  tooluniverse-systems-biology

Input Parameters

Alzheimer disease

MONDO_0004975

brain

liver

blood

genomics

transcriptomics

pathways

Multi-Omics Confidence Score (0-100)

Score Components

Data Availability (0-40 points):

• Genomics data available (GWAS or rare variants): 10 points
• Transcriptomics data available (DEGs or expression): 10 points
• Protein data available (PPI or expression): 5 points
• Pathway data available (enriched pathways): 10 points
• Clinical/drug data available (approved drugs or trials): 5 points

Evidence Concordance (0-40 points):

• Multi-layer genes (appear in 3+ layers): up to 20 points (2 per gene, max 10 genes)
• Consistent direction (genetics + expression concordant): 10 points
• Pathway-gene concordance (genes found in enriched pathways): 10 points

Evidence Quality (0-20 points):

• Strong genetic evidence (GWAS p < 5e-8): 10 points
• Clinical validation (approved drugs): 10 points

Score Interpretation

Evidence Grading System

Report Template

Create this file structure at the start:

{disease_name}_multiomic_report.md

# Multi-Omics Disease Characterization: {Disease Name}

**Report Generated**: {date}
**Disease Identifiers**: (to be filled)
**Multi-Omics Confidence Score**: (to be calculated)

---

## Executive Summary

(2-3 sentence disease mechanism synthesis - fill after all layers complete)

---

## 1. Disease Definition & Context

### Disease Identifiers
| System | ID | Source |
|--------|-----|--------|

### Description
### Synonyms
### Disease Hierarchy (parents/children)
### Affected Tissues/Organs
### Therapeutic Areas

**Sources**: (tools used)

---

## 2. Genomics Layer

### 2.1 GWAS Associations
| SNP | P-value | Effect | Gene | Study | Source |
|-----|---------|--------|------|-------|--------|

### 2.2 GWAS Studies Summary
| Study ID | Trait | Sample Size | Year | Source |
|----------|-------|-------------|------|--------|

### 2.3 Associated Genes (Genetic Evidence)
| Gene | Ensembl ID | Association Score | Evidence Type | Source |
|------|------------|-------------------|---------------|--------|

### 2.4 Rare Variants (ClinVar)
| Variant | Gene | Clinical Significance | Source |
|---------|------|-----------------------|--------|

### Genomics Layer Summary
- Total GWAS hits:
- Top genes by genetic evidence:
- Genetic architecture:

**Sources**: (tools used)

---

## 3. Transcriptomics Layer

### 3.1 Differential Expression Studies
| Experiment | Condition | Up-regulated | Down-regulated | Source |
|------------|-----------|--------------|----------------|--------|

### 3.2 Expression Atlas Disease Evidence
| Gene | Score | Source |
|------|-------|--------|

### 3.3 Tissue Expression Patterns (GTEx/HPA)
| Gene | Tissue | Expression Level | Source |
|------|--------|-----------------|--------|

### 3.4 Biomarker Candidates (Expression-Based)
| Gene | Tissue Specificity | Fold Change | Evidence | Source |
|------|-------------------|-------------|----------|--------|

### Transcriptomics Layer Summary
- Differential expression datasets:
- Top DEGs:
- Tissue-specific patterns:

**Sources**: (tools used)

---

## 4. Proteomics & Interaction Layer

### 4.1 Protein-Protein Interactions (STRING)
| Protein A | Protein B | Score | Source |
|-----------|-----------|-------|--------|

### 4.2 Hub Genes (Network Centrality)
| Gene | Degree | Betweenness | Role | Source |
|------|--------|-------------|------|--------|

### 4.3 Protein Complexes (IntAct)
| Complex | Members | Function | Source |
|---------|---------|----------|--------|

### 4.4 Tissue-Specific PPI Network
| Gene | Interaction Score | Tissue | Source |
|------|-------------------|--------|--------|

### Proteomics Layer Summary
- Total PPIs:
- Hub genes:
- Network modules:

**Sources**: (tools used)

---

## 5. Pathway & Network Layer

### 5.1 Enriched Pathways (Enrichr/Reactome)
| Pathway | Database | P-value | Genes | Source |
|---------|----------|---------|-------|--------|

### 5.2 Reactome Pathway Details
| Pathway ID | Name | Genes Involved | Source |
|------------|------|----------------|--------|

### 5.3 KEGG Pathways
| Pathway ID | Name | Description | Source |
|------------|------|-------------|--------|

### 5.4 WikiPathways
| Pathway ID | Name | Organism | Source |
|------------|------|----------|--------|

### Pathway Layer Summary
- Top enriched pathways:
- Key pathway nodes:
- Cross-pathway connections:

**Sources**: (tools used)

---

## 6. Gene Ontology & Functional Annotation

### 6.1 Biological Processes
| GO Term | Name | P-value | Genes | Source |
|---------|------|---------|-------|--------|

### 6.2 Molecular Functions
| GO Term | Name | P-value | Genes | Source |
|---------|------|---------|-------|--------|

### 6.3 Cellular Components
| GO Term | Name | P-value | Genes | Source |
|---------|------|---------|-------|--------|

**Sources**: (tools used)

---

## 7. Therapeutic Landscape

### 7.1 Approved Drugs
| Drug | ChEMBL ID | Mechanism | Target | Phase | Source |
|------|-----------|-----------|--------|-------|--------|

### 7.2 Druggable Targets
| Gene | Tractability | Modality | Clinical Precedent | Source |
|------|-------------|----------|-------------------|--------|

### 7.3 Drug Repurposing Candidates
| Drug | Original Indication | Mechanism | Target | Source |
|------|---------------------|-----------|--------|--------|

### 7.4 Clinical Trials
| NCT ID | Title | Phase | Status | Intervention | Source |
|--------|-------|-------|--------|--------------|--------|

### Therapeutic Summary
- Approved drugs:
- Clinical pipeline:
- Novel targets:

**Sources**: (tools used)

---

## 8. Multi-Omics Integration

### 8.1 Cross-Layer Gene Concordance
| Gene | Genomics | Transcriptomics | Proteomics | Pathways | Layers | Evidence Tier |
|------|----------|-----------------|------------|----------|--------|---------------|

### 8.2 Multi-Omics Hub Genes (Top 20)
| Rank | Gene | Layers Found | Key Evidence | Druggable | Source |
|------|------|-------------|--------------|-----------|--------|

### 8.3 Biomarker Candidates
| Biomarker | Type | Evidence Layers | Confidence | Source |
|-----------|------|-----------------|------------|--------|

### 8.4 Mechanistic Hypotheses
1. (Hypothesis with supporting evidence from multiple layers)
2. ...

### 8.5 Systems-Level Insights
- Key disrupted processes:
- Critical pathway nodes:
- Therapeutic intervention points:
- Testable hypotheses:

---

## Multi-Omics Confidence Score

| Component | Points | Max | Details |
|-----------|--------|-----|---------|
| Genomics data | | 10 | |
| Transcriptomics data | | 10 | |
| Protein data | | 5 | |
| Pathway data | | 10 | |
| Clinical data | | 5 | |
| Multi-layer genes | | 20 | |
| Direction concordance | | 10 | |
| Pathway-gene concordance | | 10 | |
| Genetic evidence quality | | 10 | |
| Clinical validation | | 10 | |
| **TOTAL** | | **100** | |

**Score**: XX/100 - [Tier]

---

## Data Availability Checklist

| Omics Layer | Data Available | Tools Used | Findings |
|-------------|---------------|------------|----------|
| Genomics (GWAS) | Yes/No | | |
| Genomics (Rare Variants) | Yes/No | | |
| Transcriptomics (DEGs) | Yes/No | | |
| Transcriptomics (Expression) | Yes/No | | |
| Proteomics (PPI) | Yes/No | | |
| Proteomics (Expression) | Yes/No | | |
| Pathways (Enrichment) | Yes/No | | |
| Pathways (KEGG/Reactome) | Yes/No | | |
| Gene Ontology | Yes/No | | |
| Drugs/Therapeutics | Yes/No | | |
| Clinical Trials | Yes/No | | |
| Literature | Yes/No | | |

---

## Completeness Checklist

- [ ] Disease disambiguation complete (IDs resolved)
- [ ] Genomics layer analyzed (GWAS + variants)
- [ ] Transcriptomics layer analyzed (DEGs + expression)
- [ ] Proteomics layer analyzed (PPI + interactions)
- [ ] Pathway layer analyzed (enrichment + mapping)
- [ ] Gene Ontology analyzed (BP + MF + CC)
- [ ] Therapeutic landscape analyzed (drugs + targets + trials)
- [ ] Cross-layer integration complete (concordance analysis)
- [ ] Multi-Omics Confidence Score calculated
- [ ] Biomarker candidates identified
- [ ] Hub genes identified
- [ ] Mechanistic hypotheses generated
- [ ] Executive summary written
- [ ] All sections have source citations

---

## References

### Data Sources Used
| # | Tool | Parameters | Section | Items Retrieved |
|---|------|------------|---------|-----------------|

### Database Versions
- OpenTargets: (current)
- GWAS Catalog: (current)
- STRING: (current)
- Reactome: (current)

Phase 0: Disease Disambiguation (ALWAYS FIRST)

Objective: Resolve disease to standard identifiers for all downstream queries.

Tools Used

OpenTargets_get_disease_id_description_by_name (primary):

• Input:

  diseaseName

  (string) - Disease name
• Output:

  {data: {search: {hits: [{id, name, description}]}}}

• Use: Get MONDO/EFO IDs and description
• CRITICAL: Disease IDs from OpenTargets use underscore format (e.g.,

  MONDO_0004975

  ), NOT colon format

OSL_get_efo_id_by_disease_name (secondary):

• Input:

  disease

  (string) - Disease name
• Output:

  {efo_id, name}

• Use: Get EFO/MONDO ID

OpenTargets_get_disease_description_by_efoId:

• Input:

  efoId

  (string) - Disease ID (e.g.,

  MONDO_0004975

  )
• Output:

  {data: {disease: {id, name, description, dbXRefs}}}

• Use: Get full description, cross-references (OMIM, UMLS, DOID, etc.)

OpenTargets_get_disease_synonyms_by_efoId:

• Input:

  efoId

  (string)
• Output:

  {data: {disease: {id, name, synonyms: [{relation, terms}]}}}

OpenTargets_get_disease_therapeutic_areas_by_efoId:

• Input:

  efoId

  (string)
• Output:

  {data: {disease: {id, name, therapeuticAreas: [{id, name}]}}}

OpenTargets_get_disease_ancestors_parents_by_efoId:

• Input:

  efoId

  (string)
• Output:

  {data: {disease: {id, name, ancestors: [{id, name}]}}}

OpenTargets_get_disease_descendants_children_by_efoId:

• Input:

  efoId

  (string)
• Output:

  {data: {disease: {id, name, descendants: [{id, name}]}}}

OpenTargets_map_any_disease_id_to_all_other_ids:

• Input:

  inputId

  (string) - Any known disease ID (e.g.,

  OMIM:104300

  ,

  UMLS:C0002395

  )
• Output:

  {data: {disease: {id, name, dbXRefs: [str], ...}}}

• Use: Cross-map between OMIM, UMLS, ICD10, DOID, etc.

Workflow

1. Search by disease name to get primary ID (OpenTargets)
2. Get full description and cross-references
3. Get synonyms for search term expansion
4. Get therapeutic areas for context
5. Get disease hierarchy (parents/children)
6. If user provided OMIM/other ID, map to MONDO/EFO first

Collision-Aware Search

When disease name returns multiple hits:

• Check if user's input matches any hit exactly
• If ambiguous, present top 3-5 options and ask user to select
• Always prefer the most specific disease (not parent categories)
• For cancer, prefer the specific tumor type over generic "cancer"

Key Disease IDs to Track

After disambiguation, store these for all downstream queries:

• efo_id

  - Primary ID for OpenTargets queries (e.g.,

  MONDO_0004975

  )

• disease_name

  - Canonical name (e.g.,

  Alzheimer disease

  )

• synonyms

  - For literature search expansion

• therapeutic_areas

  - For context

• dbXRefs

  - Cross-references (OMIM, UMLS, DOID, etc.)

Phase 1: Genomics Layer

Objective: Identify genetic variants, GWAS associations, and genetically implicated genes.

Tools Used

OpenTargets_get_associated_targets_by_disease_efoId (primary):

• Input:

  efoId

  (string) - Disease EFO/MONDO ID
• Output:

  {data: {disease: {id, name, associatedTargets: {count, rows: [{target: {id, approvedSymbol}, score}]}}}}

• Use: Get ALL disease-associated genes ranked by overall evidence score
• NOTE: Returns top 25 by default. For comprehensive analysis, note the total

  count

OpenTargets_get_evidence_by_datasource:

• Input:

  efoId

  (string),

  ensemblId

  (string), optional

  datasourceIds

  (array),

  size

  (int, default 50)
• Output:

  {data: {disease: {evidences: {count, rows: [{...evidence details}]}}}}

• Use: Get specific evidence types. Key datasourceIds for genomics:

  • ['ot_genetics_portal']

    - GWAS/genetics

  • ['gene2phenotype', 'genomics_england', 'orphanet']

    - Rare variants

  • ['eva']

    - ClinVar variants

gwas_search_associations (GWAS Catalog):

• Input:

  disease_trait

  (string),

  size

  (int, default 20)
• Output:

  {data: [{association_id, p_value, or_per_copy_num, or_value, beta, risk_frequency, efo_traits: [{...}], ...}], metadata: {pagination: {totalElements}}}

• Use: Get genome-wide significant associations
• NOTE: Use disease name (e.g., "Alzheimer"), not ID. Returns paginated results

gwas_get_studies_for_trait:

• Input:

  disease_trait

  (string),

  size

  (int)
• Output:

  {data: [...studies], metadata: {pagination}}

• NOTE: May return empty if trait name does not match exactly. Try synonyms

gwas_get_variants_for_trait:

• Input:

  disease_trait

  (string),

  size

  (int)
• Output:

  {data: [...variants], metadata: {pagination}}

GWAS_search_associations_by_gene:

• Input:

  gene_name

  (string)
• Output: Associations for a specific gene

OpenTargets_search_gwas_studies_by_disease:

• Input:

  diseaseIds

  (array of strings),

  enableIndirect

  (bool, default true),

  size

  (int, default 10)
• Output:

  {data: {studies: {count, rows: [{id, studyType, traitFromSource, publicationFirstAuthor, publicationDate, pubmedId, nSamples, nCases, nControls, ...}]}}}

• Use: Get GWAS studies from OpenTargets genetics portal

clinvar_search_variants:

• Input:

  condition

  (string) or

  gene

  (string), optional

  max_results

  (int)
• Output: List of ClinVar variants with clinical significance
• Use: Rare variant / monogenic disease evidence

Workflow

1. Get associated genes from OpenTargets (overall scores)
2. For top 10-15 genes, get genetic evidence specifically via

   OpenTargets_get_evidence_by_datasource

3. Search GWAS Catalog for associations
4. Search OpenTargets GWAS studies
5. Search ClinVar for rare variants
6. For top GWAS genes, check

   GWAS_search_associations_by_gene

Gene Tracking

Maintain a dictionary of genes found in genomics layer:

genomics_genes = {
    'PSEN1': {'score': 0.87, 'evidence': 'genetic', 'ensembl_id': 'ENSG00000080815', 'layer': 'genomics'},
    'APP': {'score': 0.82, 'evidence': 'genetic', 'ensembl_id': 'ENSG00000142192', 'layer': 'genomics'},
    # ...
}

Phase 2: Transcriptomics Layer

Objective: Identify differentially expressed genes, tissue-specific expression, and expression-based biomarkers.

Tools Used

ExpressionAtlas_search_differential:

• Input: optional

  gene

  (string),

  condition

  (string),

  species

  (string, default 'homo sapiens')
• Output: Differential expression studies and results
• Use: Find studies where genes are differentially expressed in disease

ExpressionAtlas_search_experiments:

• Input: optional

  gene

  (string),

  condition

  (string),

  species

  (string)
• Output: Expression experiments relevant to condition
• Use: Find all Expression Atlas experiments for the disease

expression_atlas_disease_target_score:

• Input:

  efoId

  (string),

  pageSize

  (int, required)
• Output: Genes scored by expression evidence for the disease
• Use: Get expression-based disease-gene association scores

europepmc_disease_target_score:

• Input:

  efoId

  (string),

  pageSize

  (int, required)
• Output: Genes scored by literature evidence for the disease
• Use: Complement expression evidence with literature-mined associations

HPA_get_rna_expression_by_source (Human Protein Atlas):

• Input:

  gene_name

  (string),

  source_type

  (string: 'tissue', 'blood', 'brain'),

  source_name

  (string: e.g., 'brain', 'liver')
• Output:

  {status, data: {gene_name, source_type, source_name, expression_value, expression_level, expression_unit}}

• NOTE: ALL 3 params required.

  source_type

  options: 'tissue', 'blood', 'brain', 'cell_line', 'single_cell'

HPA_get_rna_expression_in_specific_tissues:

• Input:

  gene_name

  (string),

  tissues

  (array of strings)
• Output: Expression across specified tissues

HPA_get_cancer_prognostics_by_gene:

• Input:

  gene_name

  (string)
• Output: Cancer prognostic data (if cancer context)

HPA_get_subcellular_location:

• Input:

  gene_name

  (string)
• Output: Subcellular localization data

HPA_search_genes_by_query:

• Input:

  query

  (string)
• Output: Matching genes in HPA

Workflow

1. Search Expression Atlas for differential expression studies
2. Get expression-based disease scores
3. Get literature-based disease scores (EuropePMC)
4. For top 10-15 genes from genomics layer, check tissue expression via HPA
5. Check disease-relevant tissue expression patterns
6. For cancer: check prognostic biomarkers

Gene Tracking

Add transcriptomics genes to tracking:

transcriptomics_genes = {
    'APOE': {'expression_score': 0.75, 'tissues': ['brain'], 'evidence': 'differential_expression', 'layer': 'transcriptomics'},
    # ...
}

Phase 3: Proteomics & Interaction Layer

Objective: Map protein-protein interactions, identify hub genes, and characterize interaction networks.

Tools Used

STRING_get_interaction_partners (primary PPI):

• Input:

  protein_ids

  (array of strings - gene names work),

  species

  (int, default 9606),

  confidence_score

  (float, default 0.4),

  limit

  (int, default 20)
• Output:

  {status: 'success', data: [{stringId_A, stringId_B, preferredName_A, preferredName_B, ncbiTaxonId, score, nscore, fscore, pscore, ascore, escore, dscore, tscore}]}

• Use: Get interaction partners for disease genes
• NOTE:

  protein_ids

  is an array, NOT string. Gene symbols like

  ['APOE']

  work

STRING_get_network:

• Input:

  protein_ids

  (array),

  species

  (int),

  confidence_score

  (float)
• Output: Network of interactions between input proteins
• Use: Build disease-specific PPI network

STRING_functional_enrichment:

• Input:

  protein_ids

  (array),

  species

  (int)
• Output: Functional enrichment results (GO, KEGG, etc.)
• Use: Functional characterization of disease gene set

STRING_ppi_enrichment:

• Input:

  protein_ids

  (array),

  species

  (int)
• Output: Statistical test for PPI enrichment (more interactions than expected)
• Use: Test if disease genes form a connected module

intact_get_interactions:

• Input:

  identifier

  (string - UniProt ID or gene name)
• Output: Molecular interaction data from IntAct

intact_search_interactions:

• Input:

  query

  (string),

  first

  (int, default 0),

  max

  (int, default 25)
• Output: Search results for interactions

HPA_get_protein_interactions_by_gene:

• Input:

  gene_name

  (string)
• Output:

  {gene, interactions, interactor_count, interactors: [...]}

humanbase_ppi_analysis:

• Input:

  gene_list

  (array),

  tissue

  (string),

  max_node

  (int),

  interaction

  (string),

  string_mode

  (bool)
• Output: Tissue-specific PPI network
• NOTE: ALL params required.

  interaction

  options: 'coexpression', 'interaction', 'coexpression_and_interaction'.

  string_mode

  : true/false

Workflow

1. Take top 15-20 genes from genomics + transcriptomics layers
2. Query STRING for interaction partners of each gene
3. Build composite PPI network using STRING_get_network
4. Test PPI enrichment (are genes more connected than random?)
5. Get functional enrichment from STRING
6. For disease-relevant tissue, get tissue-specific network (HumanBase)
7. Identify hub genes (highest degree centrality)
8. Check IntAct for experimentally validated interactions

Hub Gene Analysis

Calculate network centrality metrics:

• Degree: Number of interaction partners
• Betweenness: Number of shortest paths through node
• Hub score: Genes with degree > mean + 1 SD are hubs

Phase 4: Pathway & Network Layer

Objective: Identify enriched biological pathways and cross-pathway connections.

Tools Used

enrichr_gene_enrichment_analysis (primary enrichment):

• Input:

  gene_list

  (array of gene symbols, min 2),

  libs

  (array of library names)
• Output:

  {status: 'success', data: '{...JSON string with enrichment results...}'}

• Key libraries:

  ['KEGG_2021_Human']

  ,

  ['Reactome_2022']

  ,

  ['WikiPathway_2023_Human']

  ,

  ['GO_Biological_Process_2023']

  ,

  ['GO_Molecular_Function_2023']

  ,

  ['GO_Cellular_Component_2023']

• NOTE:

  data

  field is a JSON string, needs parsing. Contains

  connected_paths

  and per-library results
• NOTE:

  libs

  is REQUIRED as array

ReactomeAnalysis_pathway_enrichment:

• Input:

  identifiers

  (string - space-separated gene list), optional

  page_size

  (int, default 20),

  include_disease

  (bool),

  projection

  (bool)
• Output:

  {data: {token, analysis_type, pathways_found, pathways: [{pathway_id, name, species, is_disease, is_lowest_level, entities_found, entities_total, entities_ratio, p_value, fdr, reactions_found, reactions_total}]}}

• Use: Reactome-specific pathway enrichment with statistical testing

Reactome_map_uniprot_to_pathways:

• Input:

  id

  (string - UniProt accession)
• Output: List of Reactome pathways containing this protein
• Use: Map individual proteins to pathways

Reactome_get_pathway:

• Input:

  stId

  (string - Reactome stable ID, e.g., 'R-HSA-73817')
• Output: Pathway details

Reactome_get_pathway_reactions:

• Input:

  stId

  (string)
• Output: Reactions within pathway

kegg_search_pathway:

• Input:

  keyword

  (string)
• Output: Array of KEGG pathway matches

kegg_get_pathway_info:

• Input:

  pathway_id

  (string, e.g., 'hsa04930')
• Output: Detailed pathway information

WikiPathways_search:

• Input:

  query

  (string), optional

  organism

  (string, e.g., 'Homo sapiens')
• Output: Matching community-curated pathways

Workflow

1. Collect all genes from genomics + transcriptomics layers (top 20-30)
2. Run Enrichr enrichment for KEGG, Reactome, WikiPathways
3. Run ReactomeAnalysis for more detailed Reactome enrichment with p-values
4. Search KEGG for disease-specific pathways
5. Search WikiPathways for disease pathways
6. For top Reactome pathways, get detailed reactions
7. Identify cross-pathway connections (genes in multiple pathways)

Phase 5: Gene Ontology & Functional Annotation

Objective: Characterize biological processes, molecular functions, and cellular components.

Tools Used

enrichr_gene_enrichment_analysis (GO enrichment):

• Use with

  libs=['GO_Biological_Process_2023']

  for BP
• Use with

  libs=['GO_Molecular_Function_2023']

  for MF
• Use with

  libs=['GO_Cellular_Component_2023']

  for CC

GO_get_annotations_for_gene:

• Input:

  gene_id

  (string - gene symbol or UniProt ID)
• Output: List of GO annotations with terms, aspects, evidence codes

GO_search_terms:

• Input:

  query

  (string)
• Output: Matching GO terms

QuickGO_annotations_by_gene:

• Input:

  gene_product_id

  (string - UniProt accession, e.g., 'UniProtKB:P02649'), optional

  aspect

  (string: 'biological_process', 'molecular_function', 'cellular_component'),

  taxon_id

  (int: 9606),

  limit

  (int: 25)
• Output: GO annotations with evidence codes

OpenTargets_get_target_gene_ontology_by_ensemblID:

• Input:

  ensemblId

  (string)
• Output: GO terms associated with target

Workflow

1. Run Enrichr GO enrichment for all 3 aspects using combined gene list
2. For top 5 genes, get detailed GO annotations from QuickGO
3. For top genes, get OpenTargets GO terms
4. Summarize key biological processes, molecular functions, cellular components

Phase 6: Therapeutic Landscape

Objective: Map approved drugs, druggable targets, repurposing opportunities, and clinical trials.

Tools Used

OpenTargets_get_associated_drugs_by_disease_efoId (primary):

• Input:

  efoId

  (string),

  size

  (int, REQUIRED - use 100)
• Output:

  {data: {disease: {knownDrugs: {count, rows: [{drug: {id, name, tradeNames, maximumClinicalTrialPhase, isApproved, hasBeenWithdrawn}, phase, mechanismOfAction, target: {id, approvedSymbol}, disease: {id, name}, urls: [{url, name}]}]}}}}

• Use: All drugs associated with disease (approved + investigational)

OpenTargets_get_target_tractability_by_ensemblID:

• Input:

  ensemblId

  (string)
• Output: Tractability assessment (small molecule, antibody, PROTAC, etc.)

OpenTargets_get_associated_drugs_by_target_ensemblID:

• Input:

  ensemblId

  (string),

  size

  (int, REQUIRED)
• Output: Drugs targeting this gene/protein

search_clinical_trials:

• Input:

  query_term

  (string, REQUIRED), optional

  condition

  (string),

  intervention

  (string),

  pageSize

  (int, default 10)
• Output: Clinical trial results
• NOTE:

  query_term

  is REQUIRED even if

  condition

  is provided

OpenTargets_get_drug_mechanisms_of_action_by_chemblId:

• Input:

  chemblId

  (string)
• Output: Mechanism of action details

Workflow

1. Get all drugs for disease from OpenTargets
2. For top disease-associated genes, check tractability
3. For top genes with no approved drugs, identify repurposing candidates
4. Search clinical trials for disease
5. For top approved drugs, get mechanism of action

Drug Tracking

drug_targets = {
    'PSEN1': {'drugs': ['Semagacestat'], 'tractability': 'small_molecule', 'clinical_phase': 3},
    'ACHE': {'drugs': ['Donepezil', 'Galantamine'], 'tractability': 'small_molecule', 'clinical_phase': 4},
    # ...
}

Phase 7: Multi-Omics Integration

Objective: Integrate findings across all layers to identify cross-layer genes, calculate concordance, and generate mechanistic hypotheses.

Cross-Layer Gene Concordance Analysis

This is the core integrative step. For each gene found in the analysis:

1. Count layers: In how many omics layers does this gene appear?

   • Genomics (GWAS, rare variants, genetic association)
   • Transcriptomics (DEGs, expression score)
   • Proteomics (PPI hub, protein expression)
   • Pathways (enriched pathway member)
   • Therapeutics (drug target)

2. Score genes: Genes appearing in 3+ layers are "multi-omics hub genes"

3. Direction concordance: Do genetics and expression agree?

   • Risk allele + upregulated = concordant gain-of-function
   • Risk allele + downregulated = concordant loss-of-function
   • Discordant = needs investigation

Biomarker Identification

For each multi-omics hub gene, assess biomarker potential:

• Diagnostic: Gene expression distinguishes disease vs healthy
• Prognostic: Expression/variant predicts outcome (cancer prognostics from HPA)
• Predictive: Variant/expression predicts treatment response (pharmacogenomics)
• Evidence level: Number of supporting omics layers

Mechanistic Hypothesis Generation

From the integrated data:

1. Identify the most supported biological processes (GO + pathways)
2. Map causal chain: genetic variant -> gene expression -> protein function -> pathway disruption -> disease
3. Identify intervention points (druggable nodes in the causal chain)
4. Generate testable hypotheses

Confidence Score Calculation

Calculate the Multi-Omics Confidence Score (0-100) based on:

• Data availability across layers
• Cross-layer concordance
• Evidence quality
• Clinical validation

Phase 8: Report Finalization

Executive Summary

Write a 2-3 sentence synthesis covering:

• Disease mechanism in systems terms
• Key genes/pathways identified
• Therapeutic opportunities

Final Report Quality Checklist

Before presenting to user, verify:

• All 8 sections have content (or marked as "No data available")
• Every data point has a source citation
• Executive summary reflects key findings
• Multi-Omics Confidence Score calculated
• Top 20 genes ranked by multi-omics evidence
• Top 10 enriched pathways listed
• Biomarker candidates identified
• Cross-layer concordance table complete
• Therapeutic opportunities summarized
• Mechanistic hypotheses generated
• Data Availability Checklist complete
• Completeness Checklist complete
• References section lists all tools used

Tool Parameter Quick Reference

OpenTargets_get_disease_id_description_by_name

diseaseName

OSL_get_efo_id_by_disease_name

disease

OpenTargets_get_associated_targets_by_disease_efoId

efoId

OpenTargets_get_evidence_by_datasource

efoId

ensemblId

datasourceIds[]

size

OpenTargets_search_gwas_studies_by_disease

diseaseIds[]

size

gwas_search_associations

disease_trait

size

clinvar_search_variants

condition

gene

max_results

ExpressionAtlas_search_differential

condition

species

expression_atlas_disease_target_score

efoId

pageSize

europepmc_disease_target_score

efoId

pageSize

HPA_get_rna_expression_by_source

gene_name

source_type

source_name

STRING_get_interaction_partners

protein_ids[]

species

limit

STRING_get_network

protein_ids[]

species

STRING_functional_enrichment

protein_ids[]

species

STRING_ppi_enrichment

protein_ids[]

species

intact_search_interactions

query

max

humanbase_ppi_analysis

gene_list[]

tissue

max_node

interaction

string_mode

enrichr_gene_enrichment_analysis

gene_list[]

libs[]

ReactomeAnalysis_pathway_enrichment

identifiers

Reactome_map_uniprot_to_pathways

id

kegg_search_pathway

keyword

WikiPathways_search

query

organism

GO_get_annotations_for_gene

gene_id

QuickGO_annotations_by_gene

gene_product_id

OpenTargets_get_associated_drugs_by_disease_efoId

efoId

size

OpenTargets_get_target_tractability_by_ensemblID

ensemblId

search_clinical_trials

query_term

condition

pageSize

PubMed_search_articles

query

limit

ensembl_lookup_gene

gene_id

species

MyGene_query_genes

query

species

fields

size

OpenTargets_get_similar_entities_by_disease_efoId

efoId

threshold

size

Response Format Notes (Verified)

OpenTargets Associated Targets

{
  "data": {
    "disease": {
      "id": "MONDO_0004975",
      "name": "Alzheimer disease",
      "associatedTargets": {
        "count": 2456,
        "rows": [
          {
            "target": {"id": "ENSG00000080815", "approvedSymbol": "PSEN1"},
            "score": 0.87
          }
        ]
      }
    }
  }
}

GWAS Catalog Associations

{
  "data": [
    {
      "association_id": 216440893,
      "p_value": 2e-09,
      "or_per_copy_num": 0.94,
      "or_value": "0.94",
      "efo_traits": [{"..."}],
      "risk_frequency": "NR"
    }
  ],
  "metadata": {"pagination": {"totalElements": 1061816}}
}

STRING Interactions

{
  "status": "success",
  "data": [
    {
      "stringId_A": "9606.ENSP00000252486",
      "stringId_B": "9606.ENSP00000466775",
      "preferredName_A": "APOE",
      "preferredName_B": "APOC2",
      "score": 0.999
    }
  ]
}

Reactome Enrichment

{
  "data": {
    "token": "...",
    "pathways_found": 154,
    "pathways": [
      {
        "pathway_id": "R-HSA-1251985",
        "name": "Nuclear signaling by ERBB4",
        "species": "Homo sapiens",
        "is_disease": false,
        "is_lowest_level": true,
        "entities_found": 3,
        "entities_total": 47,
        "entities_ratio": 0.00291,
        "p_value": 4.0e-06,
        "fdr": 0.00068,
        "reactions_found": 3,
        "reactions_total": 34
      }
    ]
  }
}

HPA RNA Expression

{
  "status": "success",
  "data": {
    "gene_name": "APOE",
    "source_type": "tissue",
    "source_name": "brain",
    "expression_value": "2714.9",
    "expression_level": "very high",
    "expression_unit": "nTPM"
  }
}

Enrichr Results

{
  "status": "success",
  "data": "{\"connected_paths\": {\"Path: ...\": \"Total Weight: ...\"}}"
}

NOTE: The

data

Common Use Patterns

1. Comprehensive Disease Profiling

User: "Characterize Alzheimer's disease across omics layers"
-> Run all 8 phases
-> Produce full multi-omics report

2. Therapeutic Target Discovery

User: "What are druggable targets for rheumatoid arthritis?"
-> Emphasize Phase 1 (genomics), Phase 6 (therapeutics), Phase 7 (integration)
-> Focus on tractability and clinical precedent

3. Biomarker Identification

User: "Find diagnostic biomarkers for pancreatic cancer"
-> Emphasize Phase 2 (transcriptomics), Phase 3 (proteomics), Phase 7 (biomarkers)
-> Focus on tissue-specific expression and diagnostic potential

4. Mechanism Elucidation

User: "What pathways are dysregulated in Crohn's disease?"
-> Emphasize Phase 4 (pathways), Phase 5 (GO), Phase 7 (mechanistic hypotheses)
-> Focus on pathway enrichment and cross-pathway connections

5. Drug Repurposing

User: "What existing drugs could be repurposed for ALS?"
-> Emphasize Phase 1 (genetics), Phase 6 (therapeutic landscape), Phase 7 (repurposing)
-> Focus on drugs targeting disease-associated genes

6. Systems Biology

User: "What are the hub genes and key pathways in type 2 diabetes?"
-> Emphasize Phase 3 (PPI network), Phase 4 (pathways), Phase 7 (network analysis)
-> Focus on hub genes and network modules

Edge Case Handling

Rare Diseases (limited data)

• Genomics layer may dominate (single gene)
• Limited GWAS data (monogenic)
• Focus on ClinVar variants, pathway consequences
• Confidence score will be lower (less cross-layer data)

Common Diseases (overwhelming data)

• Thousands of GWAS associations
• Prioritize by effect size and significance
• Focus on top 20-30 genes for downstream analysis
• Use strict significance thresholds (p < 5e-8)

Cancer

• Include somatic mutations (if CIViC/cBioPortal available)
• Check cancer prognostics via HPA
• Include tumor-specific expression patterns
• Clinical trial landscape may be extensive

Monogenic Diseases

• Single gene dominates
• ClinVar/OMIM evidence is primary
• Pathway analysis reveals downstream effects
• Therapeutic landscape may be limited (gene therapy, enzyme replacement)

Polygenic Diseases

• Many weak genetic signals
• GWAS provides the gene list
• Pathway enrichment reveals convergent biology
• Network analysis identifies hub genes

Tissue Ambiguity

• Diseases affecting multiple tissues
• Query HPA for all relevant tissues
• Compare tissue-specific expression patterns
• Use tissue context from disease ontology

Fallback Strategies

If disease name not found

1. Try synonyms
2. Try broader disease category
3. Try OMIM/UMLS ID mapping
4. Report disambiguation failure and ask user

If no GWAS data

1. Check ClinVar for rare variants
2. Use OpenTargets genetic evidence
3. Note in report as "Limited genetic data"
4. Adjust confidence score accordingly

If no expression data

1. Try different disease name/synonym
2. Check HPA for individual gene expression
3. Use OpenTargets expression evidence
4. Note as "Limited transcriptomics data"

If no pathway enrichment

1. Reduce gene list stringency
2. Try different pathway databases
3. Map individual genes to pathways via Reactome
4. Note as "No significant pathway enrichment"

If no drugs found

1. Check if disease is rare/orphan
2. Look for drugs targeting individual genes
3. Check clinical trials for investigational therapies
4. Note as "No approved drugs - novel therapeutic opportunity"